{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,31]],"date-time":"2026-01-31T05:19:16Z","timestamp":1769836756650,"version":"3.49.0"},"reference-count":41,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2022,12,18]],"date-time":"2022-12-18T00:00:00Z","timestamp":1671321600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Haemophilia"],"published-print":{"date-parts":[[2023,3]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Introduction<\/jats:title><jats:p>EHL FVIII products and emicizumab provide clinicians with other prophylactic options for treating hemophilia A, however, it is unclear if emicizumab is a cost\u2010saving option. The objective of this study is to estimate the health and economic effects of using prophylactic EHL FVIII, SHL FVIII, and emicizumab in severe haemophilia A patients.<\/jats:p><\/jats:sec><jats:sec><jats:title>Materials and Methods<\/jats:title><jats:p>A state\u2010transition Markov model evaluated the cost\u2010effectiveness of prophylactic SHL FVIII, EHL FVIII, and emicizumab in a cohort of 2\u2010year\u2010old male patients over a lifetime horizon in the form of a cost\u2010utility analysis using a Canadian provincial ministry of health payer perspective. The transition probabilities, costs, and utilities were obtained from literature and the Canadian Bleeding Disorders Registry. Probabilistic sensitivity and scenario analyses were performed to test the robustness of the model.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The base\u2010case analysis, over a lifetime horizon, resulted in a total cost and utilities per person for SHL FVIII, EHL FVIII, and emicizumab of $27.2 million (M), $36.7\u00a0M, and $26.2\u00a0M, respectively, and 31.30, 31.16, and 31.61 quality\u2010adjusted life years, respectively. Emicizumab treatment resulted in 29 and 16 less bleeds in a lifetime compared to SHL FVIII and EHL FVIII, respectively. Probabilistic sensitivity analysis showed that emicizumab was cost\u2010saving 100% of the time compared to SHL FVIII and EHL FVIII.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>The cost\u2010utility analysis showed that emicizumab is more effective and may be less costly than FVIII for Canadian haemophilia A patients, conditional on drug cost assumptions. Our model indicates that emicizumab may be a potentially favourable treatment option for minimising healthcare costs and providing higher effectiveness.<\/jats:p><\/jats:sec>","DOI":"10.1111\/hae.14723","type":"journal-article","created":{"date-parts":[[2022,12,18]],"date-time":"2022-12-18T16:44:50Z","timestamp":1671381890000},"page":"488-497","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Cost\u2010utility analysis of emicizumab for the treatment of severe hemophilia A patients in Canada"],"prefix":"10.1111","volume":"29","author":[{"given":"Jacky K.","family":"Yu","sequence":"first","affiliation":[{"name":"School of Pharmacy University of Waterloo  Waterloo Ontario Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William W. L.","family":"Wong","sequence":"additional","affiliation":[{"name":"School of Pharmacy University of Waterloo  Waterloo Ontario Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arun","family":"Keepanasseril","sequence":"additional","affiliation":[{"name":"Department of Health Research Methods Evidence and Impact McMaster University  Ontario Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alfonso","family":"Iorio","sequence":"additional","affiliation":[{"name":"Department of Health Research Methods Evidence and Impact McMaster University  Ontario Canada"},{"name":"McMaster\u2010Bayer Endowed Research Chair for Clinical Epidemiology of Congenital Bleeding Disorders Department of Medicine McMaster University  Ontario Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea N.","family":"Edginton","sequence":"additional","affiliation":[{"name":"School of Pharmacy University of Waterloo  Waterloo Ontario Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2022,12,18]]},"reference":[{"issue":"9","key":"e_1_2_8_2_1","article-title":"Clotting factor concentrates given to prevent bleeding and bleeding\u2010related complications in people with hemophilia A or B","author":"Iorio A","year":"2011","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-03-378927"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1080\/14728214.2016.1220536"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-09-800326"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2007.01591.x"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/jth.14153"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1080\/17425255.2016.1214711"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.2147\/PPA.S316276"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.transci.2018.10.014"},{"key":"e_1_2_8_11_1","volume-title":"Guide to national tenders for the purchase of clotting factor concentrates","author":"O'Mahony B","year":"2015"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1017\/S0266462316000544"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/hae.14129"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2516.2003.00783.x"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2008.01664.x"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1111\/hae.13173"},{"key":"e_1_2_8_17_1","unstructured":"Canadian Agency for Drugs and Technologies in Health.CADTH Reimbursement Recommendation (Final) for Emicizumab. Published December 2020. Accessed September 19 2021. Available athttps:\/\/www.cadth.ca\/sites\/default\/files\/cdr\/complete\/ST0651%20Hemlibra%20\u2010%20CPEC%20Final%20Recommendation%20December%2023%2C%202020_for%20posting.pdf"},{"key":"e_1_2_8_18_1","unstructured":"Hemlibra (Emicizumab): Economic Review Report. Ottawa: CADTH 2019Sep. (CADTH Technology Review; no. 21)."},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.2147\/DDDT.S167731"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.5045\/br.2019.54.3.204"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1080\/03007995.2019.1649378"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019001869"},{"key":"e_1_2_8_23_1","unstructured":"Purchasing Power Parities (PPP). [cited 2021 September 1]; Available from:https:\/\/data.oecd.org\/conversion\/purchasing\u2010power\u2010parities\u2010ppp.htm"},{"key":"e_1_2_8_24_1","unstructured":"Consumer Price Index. [cited 2021 September 1]; Available from:https:\/\/www150.statcan.gc.ca\/t1\/tbl1\/en\/tv.action?pid=1810000501"},{"key":"e_1_2_8_25_1","unstructured":"Active Ingredient: Advate.2020[cited 2020 December 15]; Available from:https:\/\/www.micromedexsolutions.com"},{"key":"e_1_2_8_26_1","unstructured":"Active Ingredient: Eloctate.2020[cited 2020 December 15]; Available from:https:\/\/www.micromedexsolutions.com"},{"key":"e_1_2_8_27_1","unstructured":"Active Ingredient: Emicizumab.2020[cited 2020 December 15]; Available from:https:\/\/www.micromedexsolutions.com"},{"key":"e_1_2_8_28_1","unstructured":"Active Ingredient: NovoSeven RT.2020[cited 2020 December 15]; Available from:https:\/\/www.micromedexsolutions.com"},{"key":"e_1_2_8_29_1","volume-title":"Hip and knee replacements in Canada: CJRR quick stats, 2018\u20132019","year":"2020"},{"key":"e_1_2_8_30_1","unstructured":"Community Physiotherapy Clinic Services: Selection of Transfer Payment Recipients Application Guidelines.Ministry of Health and Long\u2010Term Care June2013."},{"key":"e_1_2_8_31_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11136-018-1848-x"},{"key":"e_1_2_8_32_1","unstructured":"Institute for Clinical and Economic Review.Emicizumab for Hemophilia A with Inhibitors: Effectiveness and Value. Final Evidence Report. Published April 16 2018. Accessed September 19 2021. Available athttps:\/\/icer.org\/wp\u2010content\/uploads\/2020\/10\/ICER_Hemophilia_Final_Evidence_Report_041618.pdf"},{"key":"e_1_2_8_33_1","doi-asserted-by":"publisher","DOI":"10.1177\/0272989X06290495"},{"key":"e_1_2_8_34_1","unstructured":"Canadian Agency for Drugs and Technologies in Health.Guidelines for the economic evaluation of health technologies: Canada. . Published March 2017. Accessed September 19 2021. Available athttps:\/\/www.cadth.ca\/sites\/default\/files\/pdf\/guidelines_for_the_economic_evaluation_of_health_technologies_canada_4th_ed.pdf"},{"key":"e_1_2_8_35_1","doi-asserted-by":"publisher","DOI":"10.1080\/13696998.2017.1405816"},{"key":"e_1_2_8_36_1","unstructured":"The tender process (RFP) for clotting factor concentrates in Canada. [cited 2021 September 12]; Available from:https:\/\/www.hemophilia.ca\/files\/What%20is%20an%20RFP.pdf"},{"key":"e_1_2_8_37_1","doi-asserted-by":"publisher","DOI":"10.1007\/s41669-019-0158-8"},{"key":"e_1_2_8_38_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2018021345"},{"key":"e_1_2_8_39_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(19)30054-7"},{"key":"e_1_2_8_40_1","doi-asserted-by":"publisher","DOI":"10.1182\/asheducation-2016.1.657"},{"key":"e_1_2_8_41_1","unstructured":"Institute for Clinical and Economic Review.Valoctocogene roxaparvovec and emicizumab for hemophilia A without inhibitors: effectiveness and value. Final Report. Published October 16 2020. Accessed September 19 2021. Available athttps:\/\/icer.org\/wp\u2010content\/uploads\/2020\/10\/ICER_Hemophilia\u2010A_Final\u2010Report_112020.pdf"},{"key":"e_1_2_8_42_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2005.01082.x"}],"container-title":["Haemophilia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/hae.14723","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/hae.14723","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/hae.14723","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,3]],"date-time":"2023-11-03T07:59:09Z","timestamp":1698998349000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/hae.14723"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,18]]},"references-count":41,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,3]]}},"alternative-id":["10.1111\/hae.14723"],"URL":"https:\/\/doi.org\/10.1111\/hae.14723","archive":["Portico"],"relation":{},"ISSN":["1351-8216","1365-2516"],"issn-type":[{"value":"1351-8216","type":"print"},{"value":"1365-2516","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,18]]},"assertion":[{"value":"2022-08-15","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-11-20","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-12-18","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}